Dennis Sullivan
Concepts (319)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 12 | 2024 | 573 | 3.440 |
Why?
| | Walking | 6 | 2024 | 105 | 2.150 |
Why?
| | Tai Ji | 3 | 2022 | 22 | 2.010 |
Why?
| | Apathy | 5 | 2020 | 41 | 1.750 |
Why?
| | Energy Intake | 7 | 2016 | 183 | 1.750 |
Why?
| | Nutrition Assessment | 6 | 2016 | 66 | 1.530 |
Why?
| | Geriatric Assessment | 7 | 2024 | 109 | 1.520 |
Why?
| | Aged | 50 | 2024 | 10242 | 1.120 |
Why?
| | Exercise Therapy | 4 | 2017 | 101 | 1.100 |
Why?
| | Muscle, Skeletal | 12 | 2018 | 799 | 1.020 |
Why?
| | Activities of Daily Living | 8 | 2017 | 185 | 1.010 |
Why?
| | Video Recording | 2 | 2024 | 79 | 0.970 |
Why?
| | Alzheimer Disease | 6 | 2018 | 356 | 0.960 |
Why?
| | Inflammation | 4 | 2012 | 649 | 0.940 |
Why?
| | Hospitalization | 4 | 2016 | 731 | 0.930 |
Why?
| | Aged, 80 and over | 26 | 2024 | 3449 | 0.920 |
Why?
| | Mortality | 5 | 2007 | 100 | 0.910 |
Why?
| | Rehabilitation Centers | 5 | 2012 | 35 | 0.900 |
Why?
| | Patient Discharge | 7 | 2023 | 320 | 0.870 |
Why?
| | Humans | 65 | 2024 | 52441 | 0.780 |
Why?
| | Patient Satisfaction | 1 | 2024 | 287 | 0.780 |
Why?
| | Nutritional Status | 7 | 2016 | 146 | 0.770 |
Why?
| | Artificial Intelligence | 1 | 2024 | 124 | 0.760 |
Why?
| | Male | 50 | 2024 | 26874 | 0.730 |
Why?
| | Frail Elderly | 3 | 2007 | 35 | 0.710 |
Why?
| | Resistance Training | 4 | 2018 | 102 | 0.710 |
Why?
| | Serum Albumin | 3 | 2012 | 57 | 0.710 |
Why?
| | Weight Gain | 5 | 2012 | 235 | 0.680 |
Why?
| | Aging | 8 | 2016 | 722 | 0.660 |
Why?
| | Muscle Weakness | 3 | 2011 | 45 | 0.660 |
Why?
| | Postural Balance | 2 | 2020 | 59 | 0.660 |
Why?
| | Advance Care Planning | 2 | 2017 | 14 | 0.650 |
Why?
| | Weight Loss | 4 | 2012 | 257 | 0.640 |
Why?
| | Head | 1 | 2020 | 70 | 0.630 |
Why?
| | Depressive Disorder | 2 | 2020 | 335 | 0.630 |
Why?
| | Accidental Falls | 2 | 2020 | 107 | 0.610 |
Why?
| | Hospitals, Veterans | 6 | 2015 | 107 | 0.590 |
Why?
| | Thigh | 1 | 2018 | 34 | 0.580 |
Why?
| | Teaching | 1 | 2019 | 112 | 0.580 |
Why?
| | Muscle Strength | 3 | 2011 | 132 | 0.580 |
Why?
| | Telemedicine | 1 | 2024 | 490 | 0.570 |
Why?
| | User-Computer Interface | 1 | 2018 | 78 | 0.570 |
Why?
| | Advance Directives | 2 | 2017 | 26 | 0.560 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2018 | 96 | 0.550 |
Why?
| | Middle Aged | 24 | 2020 | 13133 | 0.520 |
Why?
| | Megestrol Acetate | 6 | 2007 | 17 | 0.520 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2018 | 72 | 0.520 |
Why?
| | Sensation Disorders | 1 | 2017 | 11 | 0.520 |
Why?
| | Hip Fractures | 2 | 2009 | 48 | 0.520 |
Why?
| | Female | 34 | 2024 | 28277 | 0.500 |
Why?
| | Fear | 1 | 2017 | 84 | 0.490 |
Why?
| | Weight Lifting | 5 | 2007 | 29 | 0.480 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 142 | 0.480 |
Why?
| | Immune System | 1 | 2015 | 42 | 0.450 |
Why?
| | Malnutrition | 2 | 2013 | 89 | 0.450 |
Why?
| | Inpatients | 3 | 2016 | 203 | 0.450 |
Why?
| | Videoconferencing | 1 | 2015 | 38 | 0.440 |
Why?
| | Clinical Protocols | 1 | 2015 | 106 | 0.440 |
Why?
| | Exercise | 9 | 2009 | 559 | 0.440 |
Why?
| | C-Reactive Protein | 3 | 2012 | 151 | 0.440 |
Why?
| | Adaptation, Physiological | 1 | 2015 | 111 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 1140 | 0.420 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 346 | 0.400 |
Why?
| | Prospective Studies | 11 | 2017 | 2433 | 0.400 |
Why?
| | Hospital Units | 1 | 2012 | 10 | 0.390 |
Why?
| | Physical Endurance | 1 | 2012 | 35 | 0.390 |
Why?
| | Prealbumin | 2 | 2012 | 22 | 0.390 |
Why?
| | Recovery of Function | 2 | 2012 | 201 | 0.380 |
Why?
| | Leg | 1 | 2012 | 122 | 0.380 |
Why?
| | Edema | 1 | 2012 | 63 | 0.370 |
Why?
| | Nursing Homes | 2 | 2011 | 111 | 0.370 |
Why?
| | Dietary Proteins | 2 | 2012 | 247 | 0.360 |
Why?
| | Attitude to Death | 1 | 2011 | 10 | 0.350 |
Why?
| | Terminally Ill | 1 | 2011 | 12 | 0.350 |
Why?
| | Dietary Supplements | 1 | 2015 | 470 | 0.350 |
Why?
| | Assisted Living Facilities | 1 | 2011 | 11 | 0.350 |
Why?
| | Family Relations | 1 | 2011 | 23 | 0.350 |
Why?
| | Professional-Family Relations | 1 | 2011 | 43 | 0.340 |
Why?
| | Testosterone | 5 | 2005 | 145 | 0.340 |
Why?
| | Body Weight | 5 | 2012 | 524 | 0.340 |
Why?
| | Treatment Outcome | 9 | 2018 | 5508 | 0.340 |
Why?
| | Antidepressive Agents | 1 | 2012 | 176 | 0.340 |
Why?
| | Algorithms | 2 | 2024 | 673 | 0.320 |
Why?
| | Sound | 1 | 2009 | 10 | 0.310 |
Why?
| | Palliative Care | 1 | 2011 | 194 | 0.300 |
Why?
| | Muscular Diseases | 1 | 2009 | 60 | 0.290 |
Why?
| | Pilot Projects | 4 | 2018 | 725 | 0.290 |
Why?
| | Geriatrics | 1 | 2008 | 41 | 0.270 |
Why?
| | Disabled Persons | 1 | 2008 | 72 | 0.260 |
Why?
| | Food Service, Hospital | 2 | 2016 | 3 | 0.260 |
Why?
| | Photography | 2 | 2016 | 32 | 0.250 |
Why?
| | Syndrome | 2 | 2020 | 247 | 0.240 |
Why?
| | United States | 5 | 2024 | 5215 | 0.240 |
Why?
| | Hypoalbuminemia | 1 | 2005 | 4 | 0.240 |
Why?
| | Diet | 3 | 2016 | 591 | 0.230 |
Why?
| | Skin Ulcer | 2 | 2015 | 9 | 0.230 |
Why?
| | Interleukin-6 | 4 | 2012 | 271 | 0.220 |
Why?
| | Double-Blind Method | 4 | 2018 | 726 | 0.220 |
Why?
| | Methylphenidate | 2 | 2017 | 75 | 0.220 |
Why?
| | Cytokines | 1 | 2007 | 622 | 0.220 |
Why?
| | Cognition | 3 | 2018 | 363 | 0.220 |
Why?
| | Postoperative Care | 1 | 2004 | 104 | 0.210 |
Why?
| | Cohort Studies | 4 | 2012 | 1576 | 0.210 |
Why?
| | Posture | 1 | 2024 | 66 | 0.210 |
Why?
| | Enteral Nutrition | 1 | 2004 | 154 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2012 | 390 | 0.200 |
Why?
| | Body Mass Index | 7 | 2009 | 701 | 0.200 |
Why?
| | Central Nervous System Stimulants | 2 | 2017 | 198 | 0.200 |
Why?
| | Protein-Energy Malnutrition | 1 | 2002 | 16 | 0.200 |
Why?
| | Nutrition Disorders | 1 | 2002 | 11 | 0.200 |
Why?
| | Aftercare | 1 | 2023 | 67 | 0.200 |
Why?
| | Diet Records | 2 | 2016 | 19 | 0.190 |
Why?
| | Adipose Tissue | 2 | 2018 | 205 | 0.190 |
Why?
| | Body Composition | 6 | 2009 | 343 | 0.180 |
Why?
| | Prognosis | 4 | 2011 | 2100 | 0.170 |
Why?
| | Muscle Proteins | 4 | 2009 | 343 | 0.170 |
Why?
| | Risk Factors | 4 | 2016 | 3971 | 0.170 |
Why?
| | Feasibility Studies | 2 | 2015 | 404 | 0.170 |
Why?
| | Independent Living | 2 | 2017 | 47 | 0.160 |
Why?
| | Outpatients | 1 | 2020 | 128 | 0.160 |
Why?
| | Quality Improvement | 1 | 2022 | 226 | 0.160 |
Why?
| | Proportional Hazards Models | 3 | 2007 | 446 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2017 | 2294 | 0.150 |
Why?
| | Coronary Artery Disease | 1 | 2002 | 323 | 0.140 |
Why?
| | Time Factors | 4 | 2017 | 2987 | 0.140 |
Why?
| | Muscles | 2 | 2016 | 108 | 0.140 |
Why?
| | Organ Size | 1 | 2018 | 226 | 0.140 |
Why?
| | Adult | 8 | 2019 | 14205 | 0.130 |
Why?
| | Cross-Over Studies | 1 | 2018 | 236 | 0.130 |
Why?
| | Mental Status Schedule | 1 | 2017 | 17 | 0.130 |
Why?
| | Pandemics | 1 | 2022 | 580 | 0.130 |
Why?
| | Executive Function | 1 | 2018 | 85 | 0.130 |
Why?
| | Arkansas | 4 | 2008 | 2013 | 0.130 |
Why?
| | Wound Healing | 2 | 2015 | 223 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 1677 | 0.130 |
Why?
| | Meals | 1 | 2016 | 58 | 0.120 |
Why?
| | Hyperinsulinism | 2 | 2006 | 30 | 0.120 |
Why?
| | Caenorhabditis elegans | 1 | 2016 | 135 | 0.120 |
Why?
| | Health Behavior | 1 | 2017 | 256 | 0.110 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2015 | 11 | 0.110 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2015 | 34 | 0.110 |
Why?
| | Electric Stimulation Therapy | 1 | 2015 | 22 | 0.110 |
Why?
| | Obesity | 4 | 2009 | 1176 | 0.110 |
Why?
| | Bone and Bones | 1 | 2018 | 492 | 0.110 |
Why?
| | Dietary Carbohydrates | 2 | 2006 | 91 | 0.110 |
Why?
| | Length of Stay | 2 | 2008 | 673 | 0.110 |
Why?
| | Retrospective Studies | 3 | 2020 | 6694 | 0.110 |
Why?
| | Decision Making | 1 | 2016 | 273 | 0.110 |
Why?
| | Tissue Engineering | 1 | 2015 | 74 | 0.110 |
Why?
| | Electronic Health Records | 1 | 2016 | 274 | 0.110 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 106 | 0.100 |
Why?
| | APACHE | 2 | 2004 | 25 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2009 | 1004 | 0.100 |
Why?
| | Nutrition Therapy | 1 | 2013 | 20 | 0.100 |
Why?
| | Intermediate Care Facilities | 1 | 2012 | 4 | 0.100 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2013 | 17 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1223 | 0.100 |
Why?
| | Regional Blood Flow | 1 | 2012 | 109 | 0.100 |
Why?
| | Ubiquitin | 1 | 2013 | 70 | 0.100 |
Why?
| | Age Factors | 3 | 2015 | 1120 | 0.090 |
Why?
| | Proteolysis | 1 | 2013 | 100 | 0.090 |
Why?
| | Citalopram | 1 | 2012 | 16 | 0.090 |
Why?
| | Fluoxetine | 1 | 2012 | 44 | 0.090 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2013 | 137 | 0.090 |
Why?
| | Patient Care Team | 1 | 2013 | 267 | 0.090 |
Why?
| | Survival Analysis | 2 | 2003 | 656 | 0.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 148 | 0.090 |
Why?
| | Narration | 1 | 2011 | 29 | 0.090 |
Why?
| | Exercise Tolerance | 1 | 2011 | 42 | 0.090 |
Why?
| | Cognition Disorders | 1 | 2012 | 213 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2013 | 318 | 0.080 |
Why?
| | Mass Screening | 1 | 2013 | 354 | 0.080 |
Why?
| | Myofibrils | 2 | 2007 | 20 | 0.080 |
Why?
| | Rural Population | 1 | 2015 | 587 | 0.080 |
Why?
| | Abdominal Fat | 1 | 2009 | 9 | 0.080 |
Why?
| | Sleep | 1 | 2011 | 191 | 0.080 |
Why?
| | Adiponectin | 1 | 2009 | 47 | 0.080 |
Why?
| | Muscle Development | 1 | 2009 | 24 | 0.080 |
Why?
| | Polysomnography | 1 | 2009 | 76 | 0.080 |
Why?
| | Insurance Claim Review | 1 | 2009 | 41 | 0.080 |
Why?
| | Communication | 1 | 2011 | 255 | 0.080 |
Why?
| | Glucose | 2 | 2007 | 356 | 0.070 |
Why?
| | Health Status Indicators | 1 | 2008 | 81 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 938 | 0.070 |
Why?
| | Disability Evaluation | 1 | 2008 | 92 | 0.070 |
Why?
| | Electroencephalography | 1 | 2009 | 301 | 0.070 |
Why?
| | Rest | 1 | 2007 | 60 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 106 | 0.070 |
Why?
| | Hypertension | 2 | 2002 | 560 | 0.070 |
Why?
| | Weightlessness | 1 | 2007 | 13 | 0.070 |
Why?
| | Medicare | 1 | 2009 | 281 | 0.070 |
Why?
| | Space Flight | 1 | 2007 | 32 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2017 | 1045 | 0.060 |
Why?
| | Physical Education and Training | 2 | 2003 | 23 | 0.060 |
Why?
| | Glucose Clamp Technique | 1 | 2006 | 15 | 0.060 |
Why?
| | Glucose Intolerance | 1 | 2006 | 27 | 0.060 |
Why?
| | Proteins | 1 | 2009 | 353 | 0.060 |
Why?
| | Glycogen | 1 | 2006 | 44 | 0.060 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2005 | 4 | 0.060 |
Why?
| | Hormones | 1 | 2005 | 57 | 0.060 |
Why?
| | Pituitary Gland | 1 | 2005 | 87 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2004 | 17 | 0.050 |
Why?
| | Interleukin-18 | 1 | 2004 | 26 | 0.050 |
Why?
| | Registries | 1 | 2008 | 638 | 0.050 |
Why?
| | Regression Analysis | 1 | 2005 | 400 | 0.050 |
Why?
| | Diet, Fat-Restricted | 1 | 2004 | 13 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2006 | 281 | 0.050 |
Why?
| | Marital Status | 1 | 2003 | 19 | 0.050 |
Why?
| | Insulin | 1 | 2006 | 485 | 0.050 |
Why?
| | Macrophages | 1 | 2006 | 357 | 0.050 |
Why?
| | Demography | 1 | 2003 | 92 | 0.050 |
Why?
| | Models, Biological | 1 | 2006 | 735 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2003 | 292 | 0.050 |
Why?
| | Lipids | 1 | 2003 | 163 | 0.050 |
Why?
| | Chronic Disease | 2 | 2015 | 579 | 0.050 |
Why?
| | Health Status | 1 | 2004 | 300 | 0.050 |
Why?
| | Anthropometry | 1 | 2002 | 102 | 0.050 |
Why?
| | Analysis of Variance | 3 | 2012 | 558 | 0.050 |
Why?
| | Amino Acids | 1 | 2004 | 386 | 0.050 |
Why?
| | Gonadal Steroid Hormones | 1 | 2002 | 41 | 0.050 |
Why?
| | Leptin | 1 | 2003 | 148 | 0.040 |
Why?
| | Oxygen Consumption | 3 | 2009 | 193 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 234 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2003 | 609 | 0.040 |
Why?
| | Logistic Models | 1 | 2002 | 930 | 0.040 |
Why?
| | Blood Pressure | 1 | 2002 | 525 | 0.040 |
Why?
| | Ciliary Neurotrophic Factor | 2 | 2009 | 8 | 0.040 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 2 | 2009 | 29 | 0.040 |
Why?
| | Matrix Metalloproteinase 2 | 2 | 2009 | 59 | 0.040 |
Why?
| | Cholesterol | 2 | 2012 | 159 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2009 | 140 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2004 | 1065 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 580 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 110 | 0.030 |
Why?
| | Multiple Myeloma | 1 | 2011 | 3013 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 183 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2016 | 91 | 0.030 |
Why?
| | Self Report | 1 | 2016 | 221 | 0.030 |
Why?
| | Body Constitution | 2 | 2006 | 12 | 0.030 |
Why?
| | Caregivers | 1 | 2017 | 239 | 0.030 |
Why?
| | Administration, Topical | 1 | 2015 | 62 | 0.030 |
Why?
| | Canada | 1 | 2015 | 112 | 0.030 |
Why?
| | Triglycerides | 2 | 2007 | 171 | 0.030 |
Why?
| | Forecasting | 1 | 2015 | 151 | 0.030 |
Why?
| | Nutritional Support | 1 | 2013 | 31 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2007 | 1134 | 0.030 |
Why?
| | Injections, Intramuscular | 2 | 2003 | 57 | 0.030 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2013 | 22 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2013 | 15 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 637 | 0.020 |
Why?
| | Hemostasis | 1 | 2013 | 54 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2013 | 101 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2003 | 370 | 0.020 |
Why?
| | Consensus | 1 | 2013 | 195 | 0.020 |
Why?
| | Depression | 1 | 2017 | 603 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 870 | 0.020 |
Why?
| | Biomedical Research | 1 | 2015 | 260 | 0.020 |
Why?
| | Muscular Atrophy | 1 | 2011 | 73 | 0.020 |
Why?
| | Animals | 2 | 2016 | 13485 | 0.020 |
Why?
| | Spectrometry, X-Ray Emission | 1 | 2009 | 7 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 20 | 0.020 |
Why?
| | Blood Glucose | 1 | 2012 | 483 | 0.020 |
Why?
| | Quality of Life | 1 | 2015 | 893 | 0.020 |
Why?
| | Nitrogen | 1 | 2009 | 70 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 318 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 116 | 0.020 |
Why?
| | Myostatin | 1 | 2007 | 8 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 5 | 1 | 2007 | 16 | 0.020 |
Why?
| | Actins | 1 | 2007 | 112 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 136 | 0.020 |
Why?
| | Young Adult | 1 | 2016 | 4346 | 0.020 |
Why?
| | Muscle Contraction | 1 | 2007 | 109 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2009 | 315 | 0.020 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2006 | 5 | 0.020 |
Why?
| | Chemokines, CC | 1 | 2006 | 8 | 0.020 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 18 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2006 | 22 | 0.020 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 38 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2005 | 5 | 0.010 |
Why?
| | Cell Count | 1 | 2006 | 143 | 0.010 |
Why?
| | Body Fat Distribution | 1 | 2005 | 10 | 0.010 |
Why?
| | Freezing | 1 | 2005 | 15 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 81 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2006 | 102 | 0.010 |
Why?
| | Serum | 1 | 2005 | 32 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 111 | 0.010 |
Why?
| | Interleukin-1beta | 1 | 2006 | 84 | 0.010 |
Why?
| | Parenteral Nutrition Solutions | 1 | 2004 | 8 | 0.010 |
Why?
| | Solutions | 1 | 2004 | 25 | 0.010 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2004 | 21 | 0.010 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 16 | 0.010 |
Why?
| | Myosin Heavy Chains | 1 | 2004 | 25 | 0.010 |
Why?
| | Electrolytes | 1 | 2004 | 26 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 213 | 0.010 |
Why?
| | Deuterium | 1 | 2004 | 47 | 0.010 |
Why?
| | Mice | 1 | 2015 | 5899 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2004 | 127 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 212 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2004 | 63 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2004 | 123 | 0.010 |
Why?
| | Phenylalanine | 1 | 2004 | 139 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2004 | 202 | 0.010 |
Why?
| | Cell Cycle Proteins | 1 | 2004 | 168 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2003 | 39 | 0.010 |
Why?
| | Hormone Replacement Therapy | 1 | 2003 | 25 | 0.010 |
Why?
| | Phosphorylation | 1 | 2004 | 536 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 977 | 0.010 |
Why?
| | Appetite | 1 | 2003 | 14 | 0.010 |
Why?
| | Amino Acids, Essential | 1 | 2004 | 136 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2004 | 312 | 0.010 |
Why?
| | Probability | 1 | 2003 | 171 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2007 | 1099 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 594 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2004 | 267 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 316 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 625 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2002 | 404 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 871 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 1365 | 0.010 |
Why?
|
|
Sullivan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|